MDXG vs. AORT, FNA, ATRI, KIDS, ATRC, TMCI, SILK, SIBN, EMBC, and IRMD
Should you be buying MiMedx Group stock or one of its competitors? The main competitors of MiMedx Group include Artivion (AORT), Paragon 28 (FNA), Atrion (ATRI), OrthoPediatrics (KIDS), AtriCure (ATRC), Treace Medical Concepts (TMCI), Silk Road Medical (SILK), SI-BONE (SIBN), Embecta (EMBC), and Iradimed (IRMD). These companies are all part of the "surgical & medical instruments" industry.
Artivion (NYSE:AORT) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, community ranking, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.
Artivion has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.
MiMedx Group has lower revenue, but higher earnings than Artivion. Artivion is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
Artivion presently has a consensus target price of $23.50, suggesting a potential upside of 12.39%. MiMedx Group has a consensus target price of $12.25, suggesting a potential upside of 90.51%. Given Artivion's higher probable upside, analysts plainly believe MiMedx Group is more favorable than Artivion.
MiMedx Group received 20 more outperform votes than Artivion when rated by MarketBeat users. Likewise, 76.19% of users gave MiMedx Group an outperform vote while only 66.67% of users gave Artivion an outperform vote.
86.4% of Artivion shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 8.1% of Artivion shares are held by company insiders. Comparatively, 19.9% of MiMedx Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
MiMedx Group has a net margin of 14.49% compared to MiMedx Group's net margin of -8.67%. Artivion's return on equity of 41.12% beat MiMedx Group's return on equity.
In the previous week, MiMedx Group had 2 more articles in the media than Artivion. MarketBeat recorded 4 mentions for MiMedx Group and 2 mentions for Artivion. MiMedx Group's average media sentiment score of 0.76 beat Artivion's score of 0.48 indicating that Artivion is being referred to more favorably in the media.
Summary
MiMedx Group beats Artivion on 13 of the 17 factors compared between the two stocks.
Get MiMedx Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDXG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MDXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MiMedx Group Competitors List
Related Companies and Tools
